NICE and the British Thoracic Society advise against routine inhaled steroids for bronchiectasis unless asthma, COPD, or ABPA is also present.
An inhaler built for asthma can be the wrong tool for bronchiectasis, and two major guideline bodies say so in nearly identical words: a steroid inhaler is not a bronchiectasis treatment by itself.
Below is where the guidelines stand on steroids, bronchodilators, and inhaled antibiotics, plus the exceptions that justify a prescription.
Do Bronchiectasis Guidelines Recommend Inhaled Steroids?
No. NICE and the British Thoracic Society both advise against inhaled corticosteroids (ICS) given solely to prevent exacerbations. NICE’s draft bronchiectasis guideline says not to offer ICS, alone or with a long-acting beta-2 agonist, purely for exacerbation prevention, because the evidence does not show a benefit.
BTS reports no reduction in exacerbations across longer-term ICS studies and flags local and systemic adverse effects. The European Respiratory Society’s 2025 adult guideline also recommends against routine ICS.
When a second diagnosis is already on the chart, the picture changes. BTS lists these as legitimate reasons to prescribe ICS:
- Chronic asthma
- COPD
- Allergic bronchopulmonary aspergillosis (ABPA)
- Airway disease tied to inflammatory bowel disease
In each case the inhaler is chosen by that condition’s own guideline, not by the bronchiectasis diagnosis.
Bronchiectasis Inhaler Guidelines: What Decides The Prescription
The molecule, dose, and device all follow the asthma or COPD guideline in play. None of the three documents names a preferred ICS molecule, brand, inhaler type, dose, or duration for bronchiectasis — the evidence never got far enough to rank them.
Device choice is where the guidelines go quiet. Metered-dose, dry-powder, and soft-mist inhalers each demand different breathing technique, and getting that technique wrong is the most common reason a prescription underperforms. Comparing inhaler options worth comparing for bronchiectasis by device type beats picking by brand.
| Inhaler Or Therapy | Guideline Position | When It Applies |
|---|---|---|
| Inhaled corticosteroids | Not for bronchiectasis alone; no exacerbation benefit shown, with local and systemic side effects possible | Comorbid asthma, COPD, ABPA, or IBD airway disease |
| Long-acting bronchodilator | Trial offered for significant breathlessness | Breathlessness limiting daily activity |
| Short-acting beta-2 agonist | Insufficient evidence for routine bronchiectasis use | Before nebulized mucoactive therapy when bronchospasm risk is high |
| Long-term inhaled antibiotics | Strongly recommended in selected adults (ERS 2025) | Chronic Pseudomonas aeruginosa with high exacerbation risk |
| Long-term macrolides | Recommended for high-risk patients (ERS 2025) | Repeated exacerbations despite clearance therapy |
| Airway clearance therapy | Strongly recommended for most patients (ERS 2025) | Everyone with confirmed bronchiectasis |
| Pulmonary rehabilitation | Recommended (ERS 2025) | Breathlessness shrinking what you can do in a day |
What About Bronchodilators And Inhaled Antibiotics?
Bronchodilators are not automatic either. BTS recommends offering a trial of a long-acting bronchodilator to adults with significant breathlessness, noting that a good response may point to coexisting asthma, and is candid that the evidence never settled on an optimal strategy. Options span short- and long-acting beta-2 agonists, short- and long-acting anticholinergics, and combinations. The guideline found insufficient evidence for routine short-acting beta-2 agonist use, and notes that measurable reversibility on spirometry is not required to benefit.
One timing detail matters: BTS suggests considering a bronchodilator before inhaled or nebulized mucoactive treatment when bronchoconstriction is likely — in asthma, bronchial hyper-reactivity, or severe airflow obstruction with an FEV1 under 1 litre.
Inhaled antibiotics sit in a different category. ERS strongly recommends long-term inhaled antibiotics for adults with chronic Pseudomonas aeruginosa infection who remain at high exacerbation risk, and conditionally for selected other pathogens. Risk here means roughly two or more exacerbations a year, one exacerbation with severe symptoms, or at least one hospitalization-level episode annually. This is a targeted antimicrobial decision built on sputum culture results, not a swap-in for a standard inhaler.
The thread running through all of it: an inhaler in bronchiectasis should answer a specific question — is there coexisting asthma or COPD, is breathlessness the dominant problem, is chronic infection driving the exacerbations.
Common Questions
Can I Stop My Steroid Inhaler If I Have Bronchiectasis?
Not without talking to your prescriber first. If the inhaler was started for asthma, COPD, or ABPA, that diagnosis is the reason it exists, and stopping suddenly can destabilize the condition it treats. Ask why it was originally prescribed. If the only recorded reason was bronchiectasis, that is a fair question to raise at your next review.
Which Bronchodilator Works Best For Bronchiectasis?
Guidelines do not name a winner. BTS found the evidence too thin to establish an optimal strategy, so it recommends a trial of long-acting bronchodilator therapy for significant breathlessness and judging the response. Short- and long-acting beta-2 agonists, anticholinergics, and combinations are all options, and your own symptom response decides.
Is A Rescue Inhaler Enough On Its Own?
Rarely. BTS found insufficient evidence for routine short-acting beta-2 agonist use in bronchiectasis. The treatments with the strongest backing in ERS’s 2025 guideline are airway clearance therapy taught by a clinician, pulmonary rehabilitation, long-term macrolides for high-risk patients, and inhaled antibiotics for chronic Pseudomonas infection.
Sources
- National Institute for Health and Care Excellence. “Bronchiectasis (non-cystic fibrosis), acute exacerbation — draft guideline (NG117).” Supports the position that ICS should not be offered solely to prevent exacerbations.
- British Thoracic Society. “BTS Guideline for Bronchiectasis in Adults.” Source for ICS exceptions, bronchodilator trial guidance, and mucoactive timing.
- Thorax / BMJ. “BTS Guideline for Bronchiectasis in Adults (full PDF).” Full guideline text covering exacerbation evidence and adverse effects.